A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Epistemonikos ID: 97df9803ecbb1e751498b5504902a47f5c6755c6
First added on: May 14, 2024